B. Riley Securities Upgrades Bicycle Therapeutics to Buy, Maintains Price Target to $33
Portfolio Pulse from Benzinga Newsdesk
B. Riley Securities analyst Kalpit Patel has upgraded Bicycle Therapeutics (NASDAQ:BCYC) from Neutral to Buy, while maintaining the price target at $33.
September 11, 2023 | 5:58 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bicycle Therapeutics has been upgraded from Neutral to Buy by B. Riley Securities, with the price target remaining at $33.
The upgrade from Neutral to Buy indicates a positive outlook for Bicycle Therapeutics. This could potentially attract more investors, driving the stock price up in the short term. The maintained price target of $33 suggests that the analyst believes the stock is currently undervalued.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100